Examining the Potential Price Growth of Catalyst Pharmaceuticals Inc. (CPRX)


Catalyst Pharmaceuticals Inc.’s filing revealed that its President and CEO MCENANY PATRICK J unloaded Company’s shares for reported $0.35 million on May 15. In the deal valued at $13.23 per share,26,151 shares were sold. As a result of this transaction, MCENANY PATRICK J now holds 3,945,436 shares worth roughly $ 56.06 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Tierney David S sold 30,000 shares, generating $504,900 in total proceeds. Upon selling the shares at $16.83, the Director now owns 313,541 shares.

Before that, GRANDE ALICIA sold 50,000 shares. Catalyst Pharmaceuticals Inc. shares valued at $835,100 were divested by the VP, Treasurer and CFO at a price of $16.70 per share. As a result of the transaction, GRANDE ALICIA now holds 50,557 shares, worth roughly $0.72 million.

ROTH Capital downgraded its Catalyst Pharmaceuticals Inc. [CPRX] rating to a Neutral from a a Buy in a research note published on Monday, August 24, 2022; the price target was increased to $15.50 from $10. PT values the company’s stock at a premium of 8.32 to its Monday closing price.

Price Performance Review of CPRX

On Monday, Catalyst Pharmaceuticals Inc. [NASDAQ:CPRX] saw its stock fall -0.21% to $14.21. On the same session, the stock had its day’s lowest price of $14.13, but rose to a high of $14.33. Over the last five days, the stock has lost -2.67%. Catalyst Pharmaceuticals Inc. shares have fallen nearly -23.60% since the year began. Nevertheless, the stocks have fallen -0.91% over the past one year. While a 52-week high of $22.11 was reached on 01/13/23, a 52-week low of $11.09 was recorded on 06/01/23. SMA at 50 days reached $13.60, while 200 days put it at $15.36. A total of 0.53 million shares were traded, compared to the trading of 0.94 million shares in the previous session.

Levels Of Support And Resistance For CPRX Stock

The 24-hour chart illustrates a support level at 14.12, which if violated will result in even more drops to 14.02. On the upside, there is a resistance level at 14.32. A further resistance level may holdings at 14.42. The Relative Strength Index (RSI) on the 14-day chart is 52.09, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.38, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.56%. Stochastics %K at 21.64% indicates the stock is a holding.

How much short interest is there in Catalyst Pharmaceuticals Inc.?

A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc. stocks on Aug 14, 2023, dropping by -0.44 million shares to a total of 6.75 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 7.19 million shares. There was a decline of -6.52%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 8.02% of the overall stock float, the days-to-cover ratio (short ratio) fell to 4.97.

Catalyst Pharmaceuticals Inc. [CPRX] – Who Are The Largest Shareholders?

In filings from BlackRock Fund Advisors, it is revealed that the company now owns 14,310,459 shares, or roughly 13.44% of the outstanding CPRX shares. In other words, the investor’s shares have risen by 236,177 from its previous 13-F filing of 14074282.0. Additionally, SSgA Funds Management, Inc. increased 25.33% of its stake after which the total value it holdings stand at $130,736,055, while Deerfield Management Co. LP reduced -20.89% of its stake to hold $113.3 million in the firm. Over the last quarter, The Vanguard Group, Inc. sold -62,233 shares of Catalyst Pharmaceuticals Inc., while Dimensional Fund Advisors LP sold 97,902 shares. At present, Geode Capital Management LLC is holding 1,926,415 shares valued at $26.64 million. Northern Trust Investments, Inc. owned 1,368,690 shares of the company at the time of its most recent 13F filing, worth $18.93 million.

According to FactSet, Catalyst Pharmaceuticals Inc.’s share price will average $23.10 in the next year, based on opinions of analysts polled by the firm. This is up nearly 68.54 percent from its previous closing price of $14.24. Analysts expect Catalyst Pharmaceuticals Inc. stock to reach the higher price of $27.00, while the lowest price estimate is $15.50. However, 5 analysts have rated CPRX stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here